Novel Therapies Based on Autophagy Modulation: Targets, Mechanisms, and Delivery Approaches
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 20 November 2024 | Viewed by 1029
Special Issue Editors
Interests: neuroscience; neuropharmacology; neurodegenerative disorders; traumatic brain injury; animal models; behavior; neurogenomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce a Special Issue of Pharmaceutics entitled “Novel Therapies Based on Autophagy Modulation: Targets, Mechanisms, and Delivery Approaches”.
Autophagy as a process of segregation and degradation of cellular material with a subsequent use of monomers for biosynthetic and/or reparative purposes. It plays a role in cellular survival but in some minor cases of over-stimulation, it can lead to cell death. It is sometimes called a "double-edged sword". The main autophagy regulator is the mTOR protein (mammalian Target of Rapamycin), which negatively regulates autophagy. Under normal conditions, autophagy is inhibited by mTOR, while mTOR dephosphorylation leads to autophagy activation. Furthermore, non-canonical pathways independent of the mTORC1-ULK1-PI3KC3 complex and of ATG5 or ATG7 also exist.
In general, the activation of autophagy enables cell survival. This mechanism of cell repair is considered as a core one for neurons whose proliferative potential is extremely limited. Hence, the induction of autophagy is regarded as a prospective approach to the treatment of neurodegeneration. Indeed, autophagy inducers produce neuroprotective effects in cellular and animal models of different neurodegenerative diseases. Moreover, for some inducers, clinical trials have already started. On the other hand, in the early stages of tumor development, autophagy inhibits tumor growth, while later on in oncology progression, it promotes the survival of tumor cells. Therefore, effective means of suppressing autophagy for the treatment of routine cancer should be considered and tested.
This Special Issue intends to highlight recent progress in the field. We welcome all types of articles providing new insights from experimental models and human studies about treatment approaches based on autophagy modulation, with a focus on targets for pharmacological intervention, mechanisms, delivery approaches, pharmacodynamics, pharmacokinetics, bioavailability, and other issues related to the pharmaceutics of autophagy-modulating drugs.
Dr. Maria Tikhonova
Dr. Alexander B. Pupyshev
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autophagy
- neurodegeneration
- neuroprotection
- mTOR
- oncology
- pharmacodynamics
- pharmacokinetics
- anticancer therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
